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The influenza H1N1 epidemics in 2009 led a substantial number of people to develop severe acute respiratory
distress syndrome and refractory hypoxemia. In these patients, extracorporeal membrane oxygenation was used as
rescue oxygenation therapy. Several randomized clinical trials and observational studies suggested that
extracorporeal membrane oxygenation associated with protective mechanical ventilation could improve outcome,
but its efficacy remains uncertain. Organized by the Société de Réanimation de Langue Française (SRLF) in
conjunction with the Société Française d’Anesthésie et de Réanimation (SFAR), the Société de Pneumologie de Langue
Française (SPLF), the Groupe Francophone de Réanimation et d’Urgences Pédiatriques (GFRUP), the Société Française de
Perfusion (SOFRAPERF), the Société Française de Chirurgie Thoracique et Cardiovasculaire (SFCTV) et the Sociedad
Española de Medecina Intensiva Critica y Unidades Coronarias (SEMICYUC), a Consensus Conference was held in
December 2013 and a jury of 13 members wrote 65 recommendations to answer the five following questions
regarding the place of extracorporeal life support for patients with acute respiratory distress syndrome: 1) What are
the available techniques?; 2) Which patients could benefit from extracorporeal life support?; 3) How to perform
extracorporeal life support?; 4) How and when to stop extracorporeal life support?; 5) Which organization should be
recommended? To write the recommendations, evidence-based medicine (GRADE method), expert panel opinions,
and shared decisions taken by all the thirteen members of the jury of the Consensus Conference were taken into
account.
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The mortality of acute respiratory distress syndrome
(ARDS) remains high in its severe forms as defined at the
recent Berlin Consensus Conference [1]. One explanation
for this is that some patients remain severely hypoxemic
despite mechanical ventilation conducted according to
current international recommendations including, in
particular, the use of a tidal volume of between 4 and
8 mL/kg, alveolar recruitment by use of high positive* Correspondence: christian.richard@bct.aphp.fr
1Hôpitaux Universitaires Paris-Sud, Hôpital de Bicêtre, Service de Réanimation
Médicale, EA 4533, Université Paris-Sud, F- 94270 Le Kremlin-Bicêtre, France
Full list of author information is available at the end of the article
© 2014 Richard et al.; licensee Springer. This is
Attribution License (http://creativecommons.or
in any medium, provided the original work is pexpiratory pressure, prone positioning and early admin-
istration of a neuromuscular blocking agent [2]. These
patients often also present respiratory acidosis related
to the severity of decreased pulmonary compliance,
which sometimes necessitates further reduction in tidal
volume or positive expiratory pressure or both so as to
keep plateau pressure < 30 cmH2O.
Since the 1980s, extracorporeal life support techniques
(extracorporeal membrane oxygenation, ECMO) have
been proposed as a means of achieving pulmonary func-
tion recovery in severe acute respiratory failure [3]. Very
poor results and a highly unfavorable risk-benefit ratio
were seen in early studies, for two main reasons [3,4]:an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and the use of mechanical ventilation modalities which,
at that time, took insufficient account of the risk of
pulmonary baro- and volutrauma.
More recently, in the 2009 influenza A (H1N1) pan-
demic, the occurrence of severe rapid-onset ARDS causing
refractory hypoxemia prompted resurgence in the use of
ECMO in combination with protective ventilation [5-8].
Data from national and international registers suggested
that early use of ECMO gives favorable results in severe
hypoxemia [5-8].
The availability of extracorporeal life support equipment,
usually in centers with a cardiac and/or thoracic surgery
department familiar with its use in daily cardiology indica-
tions, led to the suggestion that ECMO, in particular
venovenous (VV ECMO), should henceforth be included
in the treatment algorithm for ARDS [2,9,10].
In view of the rarity of indications, the absence of for-
mal proof of the impact on prognosis, coupled with
known potentially serious risks, considerable care bur-
den, an unknown cost-benefit ratio and the absolute
need for theoretical and practical training of medical
and nursing staff, the Société de Réanimation de Langue
Française (SRLF) held a Consensus Conference to define
the modalities for use of extracorporeal life support
techniques. The different disciplines involved in the use
of these techniques during ARDS were represented
through the participation of the Société Française
d’Anesthésie et de Réanimation (SFAR), the Société de
Pneumologie de Langue Française (SPLF), the Groupe
Francophone de Réanimation et d’Urgences Pédiatriques
(GFRUP), the Société Française de Perfusion (SOFRAPERF),
the Société Française de Chirurgie Thoracique et Car-
diovasculaire (SFCTV) et the Sociedad Española de
Medecina Intensiva Critica y Unidades Coronarias
(SEMICYUC). Taking into account also the development
of extracorporeal CO2 removal [11,12], the current intro-
duction of which in France seems to be uncoordinated,
and to lack evaluation, the SRLF tasked the conference
expert panel with drawing up recommendations based
on the following five questions:
 What extracorporeal life support techniques are
available?
 Which patients require extracorporeal life support?
 How is extracorporeal life support performed?
 When and how should extracorporeal life support
be stopped?
 How should it be organized?
In formulating these recommendations, account was
taken of literature data (gathered by a Cochrane-like re-
view), data from experts and participants at the public
meeting and the opinion of the expert panel. In mostcases this enabled a consensus on the recommendations
to be reached.
Recommendations of the jury: Extracorporeal life
support for patients with acute respiratory
distress syndrome
1: What extracorporeal life support techniques are
available?
1.1 High-flow ECMO during conventional protective
ventilation improves oxygenation in cases of
refractory hypoxemia and/or corrects hypercapnia
1.2 High-flow ECMO enables implementation of
ultra-protective ventilation strategies
1.3 Low-flow extracorporeal CO2 removal (ECCO2R)
enables implementation of ultra-protective venti-
lation strategies
1.4 In ECMO, the flow rate at the drainage cannula
is an essential determinant of oxygenation
efficiency
1.5 Insertion and use of dual-lumen cannulae raises
the risk of myocardial perforation
1.6 In ECMO, the choice of insertion site and of
cannula diameters should enable generation of a
flow rate appropriate to the treatment goals
1.7 In VV ECMO in adults, the femoral-internal
jugular configuration should be preferred to gen-
erate a flow rate appropriate to the treatment
goals (CR)
1.8 In ECMO, nonocclusive centrifugal pumps
should be preferred (CR)
1.9 In ECMO, a polymethylpentene membrane
oxygenator should be preferred (CR)
2: Which patients require extracorporeal life support
in ARDS?
2.1 The indications for ECMO must be based on a
collective and multidisciplinary decision, noted
in the medical records (CR)
2.2 In ARDS, the indications for ECMO should be
discussed case by case, taking into account the
risk-benefit ratio
2.3 Before implementation of ECMO in ARDS, the
patient should be given information and his or
her consent, or that of a proxy, should be
obtained
2.4 When the patient is not in a condition to express
his/her wishes, and excepting emergency
situations, the patient’s family/friends should be
given information before implementation of
ECMO in ARDS
2.5 The predictable reversibility of lung lesions and
the absence of any other therapeutic limitation
are indispensable prerequisites to the use of
ECMO (CR)
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used unless protective ventilation, where
possible using prone positioning, has been
implemented
2.7 In children, when the PaO2 is unavailable, the
severity of ARDS can be assessed using the
SpO2/FiO2 ratio (CR)
2.8 Among extracorporeal life support techniques,
VV ECMO is the reference in severe ARDS
2.9 Current scientific knowledge precludes use of
low-flow CO2 removal techniques (ECCO2R) in
ARDS
2.10 Low-flow CO2 removal techniques (ECCO2R)
should be assessed in clinical trials (CR)
2.11 Use of VV ECMO should be considered if the
PaO2/FiO2 ratio is below 50 mmHg when
FiO2 = 1 for at least three hours, despite a
protective ventilation strategy (involving use of
prone positioning) (CR)
2.12 Use of VV ECMO should be discussed if the
PaO2/FiO2 ratio is below 80 mmHg when
FiO2 = 1 for more than six hours, despite a
protective ventilation strategy (involving use of
prone positioning) (CR)
2.13 Use of VV ECMO should be discussed if,
associated with a protective ventilation strategy
(involving use of prone positioning), there is
respiratory acidosis with a pH < 7.20 for over
six hours (CR)
2.14 There is no indication for VA ECMO in ARDS
when respiratory failure is isolated. VA ECMO
can be considered if there is concurrent
cardiogenic shock (CR)
2.15 When acute cor pulmonale prompts use of
ECMO, it is not a mandatory indication for VA
ECMO (CR)
2.16 The impossibility of using anticoagulation
treatment is a classic contraindication to
ECMO (CR)
2.17 The risk-benefit ratio of ECMO in ARDS
should be considered unfavorable in cases of
1) hemorrhagic or potentially hemorrhagic
intracranial lesions, 2) coma following cardiac
arrest, 3) ARDS in which mechanical ventilation
exceeds seven days, 4) severe immunosuppression,
5) multiorgan failure syndrome (SOFA > 15) (CR)
3: How should extracorporeal life support be
implemented in ARDS?
3.1 The setting up, priming and daily management
of ECMO should be formalized, and safety
check-lists should be used (CR)
3.2 For the implementation and management of
ECMO, medical and nursing personnel trained
in setting up the circuit should be present (CR)3.3 In ECMO, mechanical ventilation should be
adjusted to minimize plateau pressure while
administering a minimum positive expiratory
pressure
3.4 In percutaneous cannulation, emergency access
to skilled thoracic and vascular surgeons should
be organized (CR)
3.5 Ultrasound guidance should be used during
percutaneous ECMO cannulation
3.6 ECMO cannulae placement should be checked
by ultrasound and chest radiography (CR)
3.7 For optimal oxygenation in VV ECMO, the
pump blood flow should be ≥ 60% of the
theoretical cardiac output
3.8 The oxygen fraction delivered by the
extracorporeal circuit (FECO2) should give an
arterial oxygen saturation SaO2 ≥ 88%
3.9 The sweep gas rate should give a PaCO2
between 30 and 40 mmHg
3.10 Anticoagulation using unfractionated heparin
should be instituted to achieve an activated
partial thromboplastin time (aPTT) 1.2 to 1.5
times control or an anti-Xa activity between 0.2
and 0.4 IU/mL) (CR)
3.11 If there is significant bleeding, anticoagulation
should be reduced or stopped. Continuation of
ECMO should be discussed (CR)
3.12 In children, precise monitoring of hemostasis is
necessary and should include thromboelastography
and anti-Xa activity assay (CR)
3.13 In ECMO, when the pump blood flow drops
despite maintaining pump speed, check for a
reduction in preload or an increase in afterload
3.14 When implementing VV ECMO for ARDS,
hypoxemia may worsen or persist because of
reduced hypoxic pulmonary vasoconstriction,
but should prompt a search for a mechanical
cause (oxygenator failure, insufficient flow,
recirculation) (CR)
3.15 When implementing VV ECMO for ARDS,
hypoxemia may worsen because of worsening
ARDS, but should prompt a search for a
mechanical cause (oxygenator failure,
insufficient flow, recirculation) (CR)
4: When and how should extracorporeal circulation
be discontinued in ARDS?
4.1 The question of weaning from ECMO should be
posed daily (CR)
4.2 When pursuing ECMO, the question of
unreasonable obstinacy should be discussed at
collective and multidisciplinary meetings (CR)
4.3 The discontinuation of ECMO is strongly
recommended if there is a severe hemorrhagic
or embolic cerebral complication (CR)
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ECMO are no different from those in adults
(CR)
4.5 The procedure for weaning from ECMO
comprises daily checking of criteria indicative of
recovery from respiratory or cardiorespiratory
failure (CR)
4.6 On weaning from ECMO, the absence of acute
cor pulmonale should be confirmed (CR)
4.7 The decision to discontinue ECMO is based on
the results of formalized weaning over several
hours (CR)
4.8 When weaning from VA ECMO, the oxygenator
gas flow should be maintained (CR)
4.9 In ARDS, if weaning from VA ECMO is not
possible, the possibility of a switch to VV
ECMO should be considered (CR)
4.10 Anticoagulation should be stopped at least one
hour before removal of cannulae (CR)
4.11 Cannulae can be removed in the operating
theater or in intensive care (CR)
4.12 Removal of an arterial cannula is always a
surgical procedure. Removal of a venous
cannula can be medical or surgical (CR)
4.13 In children, removal of venous or arterial
cannulae is always surgical (CR)
5: What organization is needed?
5.1 As for quality and safety of care, a structured
national organization is indispensable for
optimal management of ARDS patients
requiring ECMO (CR)
5.2 Epidemic conditions apart, national organization
should enable the management of a least 300
patients a year (CR)
5.3 Implementation of ECMO should be part of the
institutional medical plan (CR)
5.4 Identification in each region of at least one
referral center possessing all human and
material means essential to the care of ARDS
patients and to the setting up and use of
extracorporeal life support techniques: critical
care, cardiac surgery and a circulatory support
mobile unit (CR)
5.5 Referral centers must have a circulatory support
mobile unit available 24/7 and ready to
intervene in all healthcare centers in the region
concerned (CR)
5.6 Each intensive care department must enter in a
national register all patients treated for severe
ARDS (CR)
5.7 Each intensive care department must be
organized through agreement to ensure the care
of ARDS patients requiring ECMO in each
region5.8 Identification in each region of at least one
intensive care department able to perform
ECMO, within a referral center or which has an
agreement with one of the referral centers (CR)
5.9 An intensive care department able to perform
ECMO in ARDS must: 1) acquire and maintain
specific skills, 2) have at least two trained
physicians in its medical personnel, 3) have
access to emergency vascular and thoracic
surgery, 4) implement a regular training
program for paramedical staff, 5) formalize the
indications and ensure their traceability, 6) enter
data in the severe ARDS registry, and 7) at least
once a year during morbidity-mortality reviews
analyze all the medical records of patients
treated with ECMO (CR)
5.10 Maintenance of the ECMO skills of an intensive
care department may be compromised if there
are fewer than ten indications for ECMO
annually
5.11 Pediatric care requires inter-regional
organization around pediatric referral centers
(specialized pediatric intensive care) with all
human and material means essential for the
care of ARDS patients and the setting up and
use of extracorporeal life support techniques:
intensive care, cardiac surgery and a circulatory
support mobile unit (CR)
5.12 To expedite ECMO in children, the pediatric
referral center (specialized pediatric intensive
care) should be contacted early (CR)Legend: aPPT, activated partial thromboplastin time;
ARDS, acute respiratory distress syndrome; CR, consensus
recommendations (recommendations that received the
majority vote of the panel); ECCO2R, low-flow extracor-
poreal CO2 removal; ECMO, extracorporeal membrane
oxygenation; FECO2, oxygen fraction delivered by the
extracorporeal circuit; SOFA, Sequential Organ Failure
score; VA ECMO, venoarterial extracorporeal membrane
oxygenation; VV ECMO, venovenous extra corporeal
membrane oxygenation.
Methodology
The GRADE system (Grading of Recommendations As-
sessment, Development and Evaluation) and a literature
analysis were used to formulate the recommendations
[13,14]. A literature search covering the period January
1994 to December 2013 was done using the databases
MEDLINE, EMBASE and CENTRAL (Cochrane Central
Register of Controlled Trials) according to a predefined
strategy (Additional file 1).
Relevant studies were selected by two people inde-
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(randomized controlled trial, cohort study, case-control
study) and its methodological quality. The selected studies
were then classified so as to group those that evaluated
predefined outcomes, and an overall level of proof for each
of these outcomes was determined taking into account the
level of proof of the individual studies. A ‘strong’ level of
proof enabled formulation of a ‘strong’ recommendation
(must be done, must not be done, the panel recom-
mends …). A ‘moderate’, ‘weak’ or ‘very weak’ level of
proof led to the drawing up of an ‘optional’ recommen-
dation (should probably be done, should probably not
be done …).
However, the type of formulation was not chosen
solely in terms of the level of proof, but also in the light
of the expert panel’s analysis of the risk-benefit ratio.
When the chosen formulation was not consensual, the
president of the expert panel called a vote. Given the
general theme of the conference and the lack of scien-
tific proof for many of the subjects dealt with, the panel
drew up ‘consensual recommendations’ put to the vote.
Recommendations that received the majority vote of the
panel are indicated in the text by CR. The panel often
wished to put forward simple statements, without pro-
posing actions. In such cases, the text was drafted using
the formulation ‘formal’ or ‘optional’.
Questions
1: What extracorporeal life support techniques are
available?
Definitions
1.1 High-flow ECMO during conventional protective
ventilation improves oxygenation in cases of
refractory hypoxemia and/or corrects hypercapnia.
1.2 High-flow ECMO enables implementation of
ultra-protective ventilation strategies.
1.3 Low-flow extracorporeal CO2 removal (ECCO2R)
enables implementation of ultra-protective
ventilation strategies.
In ARDS, several extracorporeal life support techniques
meet the objectives of oxygenation or removal of CO2
from the blood, and limitation of mechanical ventilation-
induced lung injury [9,11,15,16]. Maintained for a few days
to weeks, these techniques can result in recovery of lung
function in cases of reversible respiratory failure [6-8].
Correction of hypoxemia requires high ECMO flow rates
of about 3 to 7 L/minute. Effective CO2 removal can be
achieved with low flow rates of approximately 500 mL to
1,500 mL/minute [17].
High-flow ECMO improves oxygenation in cases of
hypoxemia refractory to conventional ventilation tech-
niques, using venovenous cannulation (VV ECMO) orvenoarterial cannulation (VA ECMO) [9]. In VV ECMO,
the venous blood is drained by a cannula inserted into a
large vein (internal jugular or femoral), oxygenated, and
reinjected into or in the immediate proximity of the
right atrium using an internal jugular or femoral cannula.
Drainage is usually from the femoral vein and the return
into the internal jugular vein. VV ECMO can be done
using a dual-lumen cannula requiring a single vascular
approach [18]. In VA ECMO, venous blood is drained
by a cannula inserted into a large vein (internal jugular
or femoral), oxygenated, and reinjected via a femoral
(end in the aorta) or axillary artery cannula [19].
Low-flow ECCO2R includes low-flow venovenous CO2
removal (VVCO2R) and arteriovenous CO2 removal
(AVCO2R) [20]. It allows removal of CO2 from the blood
and the use of ultra-protective ventilation strategies,
which reduce tidal volume and the pressure generated in
the pulmonary alveoli [12]. VVCO2R requires venous
drainage (internal jugular or femoral) and return to the
venous system (internal jugular or femoral) after extra-
pulmonary gas exchange. This technique is like continu-
ous hemofiltration, notably in terms of the use of catheters
and not cannulae [21]. It requires a pump and an exchan-
ger, separate or incorporated in a single unit. Flow rates
are generally low (300 to 1,500 mL/minute). The most
recent technologies remove CO2 more effectively with
smaller membrane areas [11,15]. AVCO2R uses the
blood flow of the patient, who must be able to generate
an arterial-venous pressure gradient ≥ 60 mmHg. Low
cardiac output compromises its use [20].
Technical aspects
1.4 In ECMO, the flow rate at the drainage cannula is
an essential determinant of oxygenation efficiency.5 Insertion and use of dual-lumen cannulae raises
the risk of myocardial perforation.
6 In ECMO, the choice of insertion site and of
cannula diameters should enable generation of a
flow rate appropriate to the treatment goals.
7 In VV ECMO in adults, the femoral-internal
jugular configuration should be preferred to
generate a flow rate appropriate to the treatment
goals (CR).
8 In ECMO, nonocclusive centrifugal pumps should
be preferred (CR).
9 In ECMO, a polymethylpentene membrane
oxygenator should be preferred (CR).ECMO circuit: connected in series, a drainage cannula,
a centrifugal pump, an oxygenator to oxygenate the blood
and remove CO2, and a return line. There is also a gas
blender and a heat exchanger to warm the blood. Any
break in the circuit upstream of the pump will lead to air
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cause blood loss. It is inadvisable to add an access to the
circuit upstream of the pump (risk of air entry) [18].
Cannulae: most cannulae are made of polyvinyl chlor-
ide or silicone. They are pre-heparinized or are coated to
increase biocompatibility [22]. The introducer must fit the
cannulae snugly to facilitate their penetration of the blood
vessel. Cannulae should be positioned along the axis of
the limb to avoid kinking, and fixed by at least three
points. The quality of fixation should be checked at each
nursing team handover. In VV ECMO, the flow rate at the
drainage cannula is an essential determinant of oxygen-
ation efficiency [22]. The maximum flow rate expected
with a cannula is proportional to its internal radius to the
power of four, and inversely proportional to its length.
The flow generated must be at least 60% of the theoretical
cardiac output of the patient in order to achieve sufficient
saturation of arterial hemoglobin [23]. To achieve this,
drainage cannulae should be 24- to 31-gauge. Cannulae
should be stiffened using a metal sheath. The use of
multiperforated drainage cannulae limits injury caused
by endothelial suction. Flow rate is less dependent on
the diameter of the return line: 16- to 23-gauge is gener-
ally sufficient to prevent the risk of hemolysis. Dual-lumen
cannulae enable both drainage and return. This type of
cannula, inserted into the internal jugular, drains the su-
perior and inferior venae cavae and enables direct return
to the tricuspid valve [18]. This type of cannula carries an
increased risk of myocardial perforation [24]. It is essential
to ensure that the guide and cannula are not in the subhe-
patic veins or at the level of the tricuspid valve, but in the
lower vena cava. In practice: femoral-jugular, femoral-
femoral, jugular-femoral and jugular (using dual-lumen
cannulae) configurations are possible. The femoral-jugular
conformation offers the best compromise between flow
rate and oxygenation [22]. The tip of the drainage cannula
in the femoral vein should be 5 to 10 cm from the inferior
vena cava-right atrium junction. The tip of the return line,
inserted into the right internal jugular, should be at the su-
perior vena cava-right atrium junction. This configuration
generally allows a pump flow rate of 5 to 6 L/minute. In
the case of femoral-femoral insertion, the tip of the
drainage cannula is 5 to 10 cm from the inferior vena
cava-right atrium junction. The tip of the return line in
the femoral artery is located in the lower part of the
right atrium [22]. The femoral-femoral configuration is
accompanied by substantial recirculation, which limits
its value. In VA ECMO, the major problem of arterial
cannulation is the risk of downstream ischemia due to
obstruction of the common femoral artery, which necessi-
tates placement downstream of a reperfusion device [22].
The tip of the return line in the femoral artery is posi-
tioned in the middle part of the ascending aorta. The tip
of the drainage cannula should be placed in the rightatrium. In practice: the femoral-femoral position is the
simplest and most used in emergencies. Return can also
be via the axillary artery [19]. This peripheral femoral-
femoral access is less complex than central access, which
requires a sternotomy. Peripheral VA ECMO, however,
does not allow left ventricular unloading. Venous drainage
being incomplete, circulation from the right atrium to the
left ventricle persists and generates flow which competes
with the blood reinjected in a retrograde fashion by the ar-
terial return line. This results in perfusion of the upper
part of the body (vascularized by the arteries originating in
the aortic arch) by imperfectly oxygenated blood, whereas
the lower part of the body receives correctly oxygenated
blood from the extracorporeal circuit (Harlequin syn-
drome). To avoid Harlequin syndrome, left ventricular
output must be reduced by inserting an additional
drainage cannula (into the right ventricle, pulmonary
artery or left ventricle) or by converting peripheral VA
ECMO into central VA ECMO [22].
Pumps: there are non-occlusive and occlusive pumps
[25,26]. Occlusive pumps are generally reserved for peri-
operative techniques in extracorporeal circulation. Non-
occlusive pumps are centrifugal pumps comprising an
electrically powered motor which spins a magnetic driver
which in turn propels the blood by means of impeller
vanes or a cone (vortex effect) or by an Archimedes screw.
They are pre- and afterload-dependent and are currently
the only ones used in Europe. These centrifugal pumps
are driven by a magnetic force which can generate speeds
of up to 7,000 rotations/minute. This magnetic force
drains the venous blood and produces a centrifugal force,
which ensures a continuous and non-pulsatile flow. Cen-
trifugal pumps maintain extracorporeal life support for a
prolonged period, with a low risk of blood stagnation
and hemolysis [27]. The pump flow rate appropriate
to the treatment goals is a function of the rotation
speed, the inlet and outlet pressures and the size of
the cannulae [28].
Oxygenator: there are two types of oxygenator; bubble
oxygenators, which are used for perioperative extracor-
poreal circulation during heart surgery, and membrane
oxygenators, which avoid hemolysis associated with bub-
bling [25,26]. Only membrane oxygenators are used for
peripheral ECMO. There are two types of membrane:
flat and tubular [28]. The former have flat silicone mem-
branes or membranes assembled in layers. Oxygenators
with tubular membranes comprising nonporous hollow
fibers generally made of polymethylpentene avoid loss of
plasma components. The oxygenator should be located
downstream of the pump and permit gas exchange by
artificially reproducing the function of the alveolar capil-
lary membrane. It also ensures heat exchange and warms
the blood of the extracorporeal circuit [25]. It has an in-
let and an outlet and is connected to a gas mixer, which
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extracorporeal circuit (FECO2) and the gas flow (sweep
gas rate). Oxygenators are tested for measurement of pres-
sure as a function of flow rates. The pressure gradient gen-
erated by the passage of the blood through the oxygenator
should be lower than 50 mmHg/L/minute. The pressure
drop corresponds to the transmembrane pressure gradi-
ent. Treatment goals distinguish oxygenation and de-
carboxylation. Membrane performance is evaluated by
the rated flow of the oxygenator which corresponds to
the amount of desaturated (75%) venous blood that can
be nearly fully saturated (95%) in a given time. The flow
rate is adjusted to that of the assist system. Most oxy-
genators support sweep flow rates of 10 mL/minute to
100 L/minute [25]. The oxygenator should be placed
below the level of the patient. The gas outlet port
should be directed downwards to limit the risk of
obstruction [25].
Pediatric specifics
In VV ECMO in children weighing under 15 kg, drainage
from the superior vena cava is recommended to obtain
a better pump flow rate, because femoral drainage with
a long, fine, resistant cannula in the right atrium results
in a pressure drop that is deleterious for the functioning
of the extracorporeal circulation [29,30]. In VA ECMO
in children under 10 kg in weight, cervical cannulation
is recommended [25]. For a body weight of 30 to 40 kg
and above, the techniques are comparable to those used
in adults.
When using a single-lumen cannula (10- to 14-gauge),
it is introduced via the right internal jugular into the
right atrium. Drainage and return by the same cannula
is permitted by means of a non-occlusive pump and suc-
cessive clamping on the drainage and injection lines
[31]. The flow rates used are a little higher (about 30%
of the cardiac output). Recirculation is low.
2: Which patients require extracorporeal life support in
ARDS?
General principles
2.1 The indications for ECMO must be based on a
collective and multidisciplinary decision, noted in
the medical records (CR).
2.2 In ARDS, the indications for ECMO should be
discussed case by case, taking into account the risk-
benefit ratio.2.3
2.4Before implementation of ECMO in ARDS, the
patient should be given information and his or
her consent, or that of a proxy, should be
obtained.
When the patient is not in a condition to express
their wishes, and excepting emergency situations,the patient’s family/friends should be given
information before implementation of ECMO in
ARDS.
2.5 The predictable reversibility of lung lesions and
the absence of any other therapeutic limitation
are indispensable prerequisites to the use of
ECMO (CR).
2.6 When ARDS is severe, ECMO should not be
used unless protective ventilation, where
possible using prone positioning, has been
implemented.
2.7 In children, when the PaO2 is unavailable, the
severity of ARDS can be assessed using the
SpO2/FiO2 ratio (CR).ARDS is a progressive inflammatory lung disease with
a heterogeneous distribution of alveolar capillary mem-
brane involvement. These lesions progressively cause gas
exchange abnormalities which result in respiratory dis-
tress [10]. In addition to treatment of the cause, respi-
ratory assistance is necessary in severe forms. However,
it has been shown that mechanical ventilation itself
worsens lung lesions. Experimental studies and clinical
trials have shown that such ventilator-induced lung in-
juries can be reduced by optimizing the ventilator set-
tings [2]. In a severe form of ARDS, it is therefore not
reasonable to use extracorporeal life support unless a
protective ventilation strategy has been implemented,
based on [1]:
 tidal volume between 4 and 8 mL/kg of the body
weight predicted by height;
 high positive end-expiratory pressure (PEEP);
 plateau pressure ≤ 30 cmH2O;
 neuromuscular blocking agent during the first
48 hours;
 trial of prone positioning [32].
In children weighing less than 20 kg, optimization of
mechanical ventilation may require the use of the high-
frequency oscillatory ventilation [33].
Given the current level of proof of clinical studies of
ECMO in ARDS, of the medical and economic impact
of the spread of these techniques, and of the consider-
able accompanying care load, the indications should be
discussed case by case in the light of the individual risk-
benefit ratio. Before implementing these techniques, the
patient should be given information and his or her con-
sent or that of a proxy obtained. In the case of children,
the legislation (article R.1112-35 of the Public Health
Code) on surgical procedures requires the authorization
of the person who holds parental authority. The expected
reversibility of lung lesions and the absence of any other
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ARDS
2.1 Among extracorporeal life support techniques, VV
ECMO is the reference in severe ARDS.
2.2 Current scientific knowledge precludes use of
low-flow CO2 removal techniques (ECCO2R) in
ARDS.
3.3 ECCO2R techniques should be assessed in clinical
trials (CR).
The negative results of two randomized, prospective,
multicenter studies published in 1979 and 1994 [4,34]
on its use in management of severe ARDS (PaO2/FiO2 <
50 mmHg) led to the abandonment of ECMO. The rea-
sons for the failure of ECMO reported in these studies
were various: late use of ECMO after a period of prolonged
mechanical ventilation associated with approximately 90%
mortality, use of VA ECMO with the associated risk of
cerebral hypoxemia secondary to Harlequin syndrome, a
high frequency of cerebral hemorrhagic complications and
use of nonprotective ventilation modalities underlying a
high incidence of pulmonary baro- and volutrauma [4,34].
Taking into account the concepts of lung rest and of
the need to minimize intraalveolar pressure in positive
pressure mechanical ventilation, numerous observational
studies have reported, in particular on the initiative of
Gattinoni et al. [3], about 50% survival [9].
More recently, the 2009 H1N1 influenza epidemic,
given the very severe forms of ARDS observed in young
subjects, led to improvements in equipment (cannulae,
pumps and membranes), sharpened understanding of
protective ventilation modalities, and renewed interest
in the use of ECMO. The analysis of observational stud-
ies [5-8] suggests a beneficial effect in terms of survival,
in particular for patients with severe ARDS, even though
other observational studies by teams not using ECMO
have reported comparable effects [35].
The only randomized, prospective study of ECMO to-
gether with protective ventilation was done by Peek et al.
in 180 patients with severe ARDS (Murray score > 3 or
pH < 7.20). It showed a significant reduction in a compos-
ite criterion combining mortality and severe handicap at
six months (37 versus 53%) in patients on ECMO, com-
pared with conventional ventilatory support [7]. Even if
the protocol of this study, which included transfer to a re-
ferral center of patients in the ECMO arm and routine use
of protective ventilation only in the same arm, does not
allow comparison of ECMO with optimized management
of ARDS, it highlights the value of resorting to a center
skilled in the use not only of ECMO, but also in the treat-
ment of severe ARDS.
This publication also underscored that a mobile team is
valuable for the transfer of unstable and severely hypoxicpatients and raised the question of how the volume effect
impacts trained teams familiar with the data on ECMO
use [7]. Despite the insufficient level of proof provided by
this literature review, the jury of the Consensus Confer-
ence considers that there are consensual indications for
the use of VV ECMO.
In contrast, given the clinical data currently available,
ECCO2R is not recommended in ARDS. However, ECCO2R
could facilitate implementation of ventilation strategies
more protective than those recommended today, so as
to limit lung injury further in mechanical ventilation.
For example, by the use of tidal volumes < 4 mL/kg of
predicted body weight and plateau pressures < 25 cmH2O.
These indications should be assessed in prospective
clinical trials [12].
Indications for ECMO
2.1 Use of VV ECMO should be considered if the
PaO2/FiO2 ratio is below 50 mmHg when FiO2 = 1
for at least three hours, despite a protective
ventilation strategy (involving use of prone
positioning) (CR).
2.2 Use of VV ECMO should be discussed if the PaO2/
FiO2 ratio is below 80 mmHg when FiO2 = 1 for
more than six hours, despite a protective
ventilation strategy (involving use of prone
positioning) (CR).
Use of VV ECMO should be discussed if,
associated with a protective ventilation strategy
(involving use of prone positioning), there is
respiratory acidosis with a pH < 7.20 for over six
hours (CR).
There is no indication for VA ECMO in ARDS
when respiratory failure is isolated. VA ECMO can
be considered if there is concurrent cardiogenic
shock (CR).
When acute cor pulmonale prompts use of ECMO,
it is not a mandatory indication for VA ECMO (CR).Despite the insufficient level of proof provided by
this literature review, the jury of the Consensus Con-
ference considers that the use of VV ECMO should
nonetheless be considered if hypoxemia results in a
PaO2/FiO2 ratio < 50 mmHg (measured when FiO2 = 1)
for over three hours. Given the predictable progression
of lung injury and the time required to implement VV
ECMO, the jury considers it reasonable to think ahead
and start collective consideration of its possible use
when hypoxemia persists for over six hours, with a
PaO2/FiO2 ratio < 80 mmHg and/or respiratory acid-
osis with a pH < 7.20. The indications for VA ECMO in
ARDS are extremely limited, but can be discussed
when there is concurrent cardiogenic shock [36].
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2.1 The impossibility of using anticoagulation treatment
is a classic contraindication to ECMO (CR).
2.2 The risk-benefit ratio of ECMO in ARDS should be
considered unfavorable in cases of 1) hemorrhagic
or potentially hemorrhagic intracranial lesions,
2) coma following cardiac arrest, 3) ARDS in which
mechanical ventilation exceeds seven days,
4) severe immunosuppression, 5) multiorgan failure
syndrome (Sequential Organ Failure Assessment
score (SOFA) > 15) (CR).
The only absolute contraindication to ECMO is the
impossibility of using anticoagulation treatment [9]. Even
though the literature provides no definitive argument in
favor of relative contraindications, it appears that ECMO
is likely to be less beneficial in certain subgroups of pa-
tients. In collective discussion of the indication for extra-
corporeal life support, account should therefore be taken
of the occurrence of ARDS in the following situations
[28]: cerebral hemorrhage, post-cardiac arrest coma when
the neurologic state can be assessed objectively, mechan-
ical ventilation lasting > seven days, severe immunosup-
pression, and multiorgan failure with a SOFA score > 15.
3: How should extracorporeal life support be
implemented in ARDS?
General principles
3.1 The setting up, priming and daily management of
ECMO should be formalized, and safety check-lists
should be used (CR).
3.2 For the implementation and management of
ECMO, medical and nursing personnel trained in
setting up the circuit should be present (CR).
3.3 In ECMO, mechanical ventilation should be
adjusted to minimize plateau pressure while
administering a minimum positive expiratory
pressure.
ECMO is an exceptional procedure which requires
formalized monitoring including safety check-lists use of
which has proven effective in the operating theater for
extracorporeal circulation procedures [37]. The main as-
pects of monitoring include regular checking of pump
speeds and the resulting flow rates. As the pump battery
allows only one hour of operation, the electricity supply
should be checked regularly. The pump and the circuit
are fitted with alarms that signal flow reversal. Daily
checks should be made on manual cranking of the pump
for use in the event of a power failure, on the availability
of a pump head for emergency replacement of a mal-
functioning pump, and on clamps. There should also beroutine checks for complications (bleeding, cannula con-
tamination, embolism, hemolysis).
This specific monitoring requires trained personnel
able to act quickly in the event of a complication and
capable of restoring an ECMO circuit at any time. As an
example, highly trained personnel are required for re-
moval of bubbles from an ECMO circuit, which is a
crucial step associated with the risk of gas embolism.
Ideally, these personnel should include a perfusionist
used to managing ECMO circuits who will participate
in the training of the medical and nursing staff.
Whatever the mode of ventilation chosen, it should be
protective in ECMO. Recent data show that patients on
ECMO survive better when the median plateau pressure
is around 25 cm H2O [8]. The respiratory frequency can
be lowered to under ten cycles a minute, while FiO2 is
progressively reduced to below 0.6 (at the same time as
FECO2) [8]. In ECMO, the use of so-called ‘ultra-protect-
ive’ ventilation with volumes below 3 mL/kg should be
evaluated in terms of prognosis [12].
Cannulation
3.4 Vascular surgeon availability should be organized
(CR).
3.5 Ultrasound guidance should be used during
percutaneous ECMO cannulation.
3.6 ECMO cannula placement should be checked by
ultrasound and chest radiography (CR).
Two operators are required to set up VV ECMO in
conditions of surgical asepsis. In the absence of a heart
surgeon during percutaneous cannulation, it is neces-
sary to have emergency access to skilled thoracic and
vascular surgeons [18]. Complications, sometimes lethal
(hemorrhage, misdirection, dissection, perforation), during
cannulation are described in nearly 10% of cases. As
regards existing recommendations for vascular puncture
in intensive care, ultrasound guidance is recommended.
Surgical femoral-femoral cannulation is the reference
route for VA ECMO and requires surgical skill. The
complications associated with VA ECMO are numerous,
and sometimes rapidly fatal, which justifies manage-
ment by medical and surgical teams used to implant-
ation techniques, but also to the management of their
complications.
Ultrasound is indispensable during the setting up and
implementation of ECMO [38,39]. Guide wire insertion
and placement of cannulae can be monitored using trans-
thoracic ultrasound at the bedside, thus limiting the
phenomenon of recirculation linked to poor position-
ing. The positioning of dual-lumen cannulae is particu-
larly difficult, and several techniques have been put
forward to improve insertion and prevent complications
Table 1 Hypoxemia during extracorporeal membrane
oxygenation (ECMO): causes and recommendations
Causes Recommendations
Recirculation Check the position of the
cannulae
Low flow with regards to metabolic
demand
Adapt the diameter of the
cannulae and correct
hypovolemia
Failure of the oxygenator Measure post-oxygenator blood
gases
Inhibition of hypoxic pulmonary
vasoconstriction and worsening of
the pulmonary shunt
Measure pre, post-oxygenator
and patient blood gases
Worsening of the pulmonary disease
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tion and detect any preload dependence.
ECMO settings
3.1 For optimal oxygenation in VV ECMO, the pump
blood flow should be ≥ 60% of the theoretical
cardiac output.
3.2 The oxygen fraction delivered by the
extracorporeal circuit (FECO2) should give an
arterial oxygen saturation SaO2 ≥ 88%.
3.3 The sweep gas rate should give a PaCO2 between
30 and 40 mmHg.
The settings are adjusted on the pump console. Pump
speed should be above 1,500 rotations/minute. Centrifugal
pumps can generate speeds up to 7,000 rotations/minute.
The ideal speed is between 3,000 and 3,500 rotations/
minute. The pump flow rate measured by an ultrasound
probe should be above 2 L/minute. At the oxygenator, the
sweep gas rate, which conditions the PaCO2 of the patient,
should be one to two times the pump flow rate [25].
Extracorporeal circuit anticoagulation
3.1 Anticoagulation using unfractionated heparin
should be instituted to achieve an activated partial
thromboplastin time (aPTT) 1.2 to 1.5 times
control or an anti-Xa activity between 0.2 and
0.4 IU/mL) (CR).
3.2 If there is significant bleeding, anticoagulation
should be reduced or stopped. Continuation of
ECMO should be discussed (CR).
3.3 In children, precise monitoring of hemostasis is
necessary and should include thromboelastography
and anti-Xa activity assay (CR).
The main complications of ECMO are hemorrhagic.
Their incidence is close to 50% [42]. Intracranial bleed-
ing was seen in 10 to 12% of cases where the level of
anticoagulation was highest (target aPTT around twice
the control) and in 2 to 4% of cases in the REVA registry
(French H1N1 influenza research network on mechanical
ventilation) with lower levels of anticoagulation [8]. Data
on circuit coagulation are scarce, but its incidence is prob-
ably about 15 to 20% and seems to decrease notably with
heparin-coated circuits.
The risk-benefit ratio favors the use of the lowest levels
of anticoagulation plus high pump speeds. It is usual to
use a heparin bolus during cannulation. Thromboelasto-
graphy has been proposed for monitoring of coagulation,
particularly in pediatrics.
ECMO, like any extracorporeal circulation, can favor
production of anti-PF4 antibodies and hence acuteheparin-induced thrombocytopenia [43]. Although the
heparin doses are lower with ECMO, it is advisable to
consider this diagnosis when there is unexplained
thrombocytopenia. Even though its deficiency, which
causes resistance to heparin, occurs at low frequency,
antithrombin III should be assayed because of the serious
consequences of circuit coagulation and the recognized
value of antithrombin III replacement therapy in restoring
the efficacy of heparin.
Causes of extracorporeal circuit malfunction
3.1 In ECMO, when the pump blood flow drops
despite maintaining pump speed, check for a
reduction in preload or an increase in afterload.
3.2 When implementing VV ECMO for ARDS,
hypoxemia may worsen or persist because of
reduced hypoxic pulmonary vasoconstriction, but
should prompt a search for a mechanical cause
(oxygenator failure, insufficient flow, recirculation)
(CR).
3.3 When implementing VV ECMO for ARDS,
hypoxemia may worsen because of worsening
ARDS, but should prompt a search for a
mechanical cause (oxygenator failure, insufficient
flow, recirculation) (CR).
The main causes of reduced preload are hypovolemia
and drainage cannula malfunction (thrombosis, movement
of cannulae). The main cause of increased afterload is
return line malfunction (thrombosis, movement of can-
nulae). Hypovolemia is also identifiable by shaking of
the circuit lines. Too high a flow rate can cause suction
in the zones of venous drainage, resulting in damage to
the vascular endothelium. The risk then is a drop in
pump flow rate because of failure of the assist system.
The main causes of persistent hypoxemia are listed in
Table 1. In these situations, remember that oxygen trans-
port also depends on cardiac output and hemoglobin level,
parameters which can be modified.
4.5
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In children weighing less than 10 kg (blood volume
80 mL/kg), priming with saline of a circuit more than
200 mL in volume may result in hemodilution. It is
therefore necessary to fill the circuit with blood, or fresh
plasma, or albumin [44]. Hemofiltration coupled with
ECMO allows adjustment of fluid-electrolyte balance
and caloric intake [45]. Monitoring of brain tissue oxy-
genation using near-infrared spectroscopy has been pro-
posed [46]. The frequency of cerebrovascular accidents
reported in children is higher than in adults. These may
be ischemic (frequency 4%) or hemorrhagic (6%) [42]. VA
ECMO is associated with more central nervous system in-
jury than VV ECMO [47,48]. In this context, monitoring
of anticoagulation by means of thromboelastography and
anti-Xa activity assay is desirable. Lastly, prone positioning
improves the prognosis of children on ECMO [49].
4: When and how should extracorporeal circulation be
discontinued in ARDS?
General principles
4.1 The question of weaning from ECMO should be
posed daily (CR).
4.2 When pursuing ECMO, the question of
unreasonable obstinacy should be discussed at
collective and multidisciplinary meetings (CR).
4.3 The discontinuation of ECMO is strongly
recommended if there is a severe hemorrhagic or
embolic cerebral complication (CR).
4.4 In children, the modalities of weaning from ECMO
are no different from those in adults (CR).
ECMO is an intensive treatment requiring high levels
of care and is associated with potentially serious compli-
cations. It should be used as briefly as possible and the
question of lung function recovery, and hence discon-
tinuation of ECMO, should be posed daily.
ECMO should be stopped when its continuation seems
to involve unreasonable obstinacy. In this context no pre-
cise criterion for discontinuation of ECMO has been de-
termined. It has been reported that several weeks may be
necessary for recovery and normalization of pulmonary
function [9,22,50]. Certain clinical criteria observed from
the first days of ECMO were associated with a poor prog-
nosis, such as no improvement in plateau pressure, blood
lactate, or hemodynamic failure [8,23,51]. In the literature,
ECMO is used for a mean period of two weeks, after
which the question of withdrawal should take the form of
a collective discussion taking into account, as when any
active treatment is limited, expected reversibility of lung
and/or cardiac failure and of other organ failures, the con-
text and in exceptional circumstances the existence of al-
ternative treatment options, such as lung transplantation.If it is decided to discontinue ECMO, the reasons should
be explained to the patient’s family/proxies.
Practical aspects of weaning from ECMO
4.1 The procedure for weaning from ECMO comprises
daily checking of criteria indicative of recovery
from respiratory or cardiorespiratory failure (CR).
4.2 On weaning from ECMO, the absence of acute cor
pulmonale should be confirmed (CR).
4.3 The decision to discontinue ECMO is based on the
results of formalized weaning over several hours
(CR).
4.4 When weaning from VA ECMO, the oxygenator
gas flow should be maintained (CR).
In ARDS, if weaning from VA ECMO is not
possible, the possibility of a switch to VV ECMO
should be considered (CR).Weaning from VV ECMO is done before weaning
from mechanical ventilation. It would be worth assessing
the value of extubation before ECMO weaning to enable
earlier mobilization of patients on ECMO.
During weaning from ECMO, it is advisable to gauge
the impact of changing the sweep gas rate on the blood
carbon dioxide level, variations in which can be deleteri-
ous, particularly in the cerebral circulation. If hypercapnia
is persistent, low-flow CO2 removal should be considered,
but its usefulness has not been assessed.
There are no data justifying the use of corticosteroids
in weaning from ECMO.
Recovery from respiratory or cardiorespiratory failure
indicated by improvement in clinical (notably in respira-
tory system compliance), blood gas, and radiological pa-
rameters is essential before weaning from ECMO [7,16,28]
Literature data [22,51,52] show that discontinuation of
VV ECMO can be considered when weaning involves
reductions in:
 sweep gas flow through the membrane until it is
zero;
 FECO2 by about 21%.
A pump flow reduction involves the risk of circuit
coagulation and is not, according to many experts, rou-
tinely necessary when envisaging weaning.
When the weaning trial is prolonged, a high-flow gas
mixture should be passed over the oxygenator mem-
brane for 30 seconds every hour. Discontinuation of VV
ECMO is decided when hematosis and plateau pressure
are deemed satisfactory (Table 2) [18,28,52,53]. Weaning
from VA ECMO is less well codified, but criteria similar
to those used for weaning from VV ECMO have been
proposed (Table 2). Unlike VV ECMO, gas flow over the
Table 2 Weaning from extracorporeal membrane oxygenation (ECMO)
Weaning trial Criteria for ECMO withdrawal
Venovenous ECMO FECO2 = 21% Pplat < 25 to 30 cmH2O with TV around 6 ml/kg and PEEP < 12 cmH2O
Sweep gas flow 1 L/minute or stopped and PaO2 > 70 mmHg on FiO2 < 60% or PaO2/FiO2 > 200 mmHg
Duration: several hours and pH > 7.3 with PCO2 < 50 mmHg
and no acute cor pulmonale
Arteriovenous ECMO FECO2 = 21% Pplat < 25 to 30 cmH2O with TV around 6 ml/kg and PEEP < 12 cmH2O
Sweep gas flow 1 L/minute and PaO2 > 70 mmHg on FiO2 < 60% or PaO2/FiO2 > 200 mmHg
Reduce pump blood flow by steps of 0.5 L/minute and pH > 7.3 with PCO2 < 50 mmHg
Duration: several hours and no acute cor pulmonale
without left ventricular failure:
left ventricular ejection fraction > 25 to 30%
velocity-time integral > 12 cm
FECO2, oxygen fraction delivered by the extracorporeal circuit; Pplat, plateau pressure; PEEP, positive end-expiratory pressure; TV, tidal volume.
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venous blood into the peripheral arterial system. A
residual flow rate of 1 L/minute is generally used. If the
patient cannot be weaned from VA ECMO, a switch to
VV ECMO should be discussed, VA ECMO being sub-
ject to more complications than VV ECMO. Whatever
the type of ECMO, right ventricular dysfunction occur-
ring during weaning should be evaluated. If weaning
from VV ECMO fails because of the onset of right
cardiac insufficiency, a switch to VA ECMO can be
considered.
Removal of cannulae
4.1 Anticoagulation should be stopped at least one
hour before removal of cannulae (CR).
4.2 Cannulae can be removed in the operating theater
or in intensive care (CR).
4.3 Removal of an arterial cannula is always a surgical
procedure. Removal of a venous cannula can be
medical or surgical (CR).
4.4 In children, removal of venous or arterial cannulae
is always surgical (CR).
5: What organization is needed?
Organization at a national level is needed to enable the
use of extracorporeal life support, in particular ECMO,
in severe ARDS. This organization should have at least
the four following objectives:
 offer access to ECMO to all patients who need it in
optimal safety conditions;
 spread facilities to allow optimal coverage
countrywide;
 be able to cope with a rapid and large increase in
the number of patients to be treated in an epidemic;
 take into account the importance of the risk-benefit
and cost-benefit ratios of ECMO.Epidemiological data on the incidence, severity and
prognosis of ARDS in France are insufficient for reliable
estimation of the number of patients requiring ECMO.
Expert opinion is that, epidemic conditions apart, every
year five to ten patients with severe ARDS per million
inhabitants require ECMO. A survey by the SRLF and
the SFAR in 2012 in 116 intensive care departments
showed that approximately 300 ARDS patients were
treated by ECMO in 58 departments, which is consistent
with the expert opinion. Lastly, an SRLF request to the
national database of the PMSI showed that, although the
data are difficult to interpret, in 2012 there were 679
stays in intensive care by patients diagnosed with ARDS
who underwent VV ECMO or VA ECMO, which is a
total of 5,325 days of treatment.
Advances in techniques and equipment suggest that
VV ECMO can be performed safely by most intensive
care departments already familiar with the management
of other modes of extracorporeal circulation, such as
dialysis and continuous hemofiltration, subject to regular
specific training. However, because of the potential ser-
iousness of complications associated with ECMO, and
because of the skills needed for management of such
treatment, experts recommend that patients requiring
VV ECMO or VA ECMO be managed in centers with all
the means needed to define the indications for ECMO
and to implement and manage it in safe conditions. The
centers best suited to this seem to be those caring both
for severe ARDS patients treated with VV ECMO and the
more numerous patients requiring VA ECMO for cardiac
reasons. This presupposes that the centers have at least an
intensive care department, a cardiac surgery department,
and a circulatory support mobile unit. As an example, this
concept of concentration of facilities was adopted by
countries like the UK and Australia, but not by others,
such as Germany and Japan. The literature evidence of the
advantages of such centralized organization, in terms of
patient outcome and cost-effectiveness ratio is, however,
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most recent pediatric studies, the number of patients
treated by ECMO (volume effect associated with this cen-
tralized organization) is determinant for the acquisition of
the required expertise [54,55].
Most reports indicate that circulatory support mobile
units play a determinant role [56-58]. However, in France
such units do not cover the whole country for adults or
for children, and for the latter there are few centers that
use ECMO and even fewer specialized circulatory support
mobile units.
Lastly, it is essential to take into consideration the
major difficulties that France would face in the event of
viral pandemic. The capacity of the centers receiving pa-
tients requiring ECMO would soon be exceeded, as was
reported during the 2009 H1N1 influenza epidemic [59].
In such a situation it is important that some centers
quickly become operational. The proposed organization
must cope with the rapid and large increase in the num-
ber of patients to be treated during an epidemic.
In view of these comments, the jury of the Consensus
Conference made the following recommendations con-
cerning the general principles of organization on a
national scale and in intensive care departments for
the care of ARDS patients likely to require ECMO.
General organizational principles
5.1 As for quality and safety of care, a structured national
organization is indispensable for optimal management
of ARDS patients requiring ECMO (CR).
5.2 Epidemic conditions apart, national organization
should enable the management of a least 300
patients a year (CR).
5.3 Implementation of ECMO should be part of the
institutional medical plan (CR).
5.4 Identification in each region of at least one referral
center possessing all human and material means
essential to the care of ARDS patients and to the
setting up and use of extracorporeal life support
techniques: critical care, cardiac surgery and a
circulatory support mobile unit (CR).
5.5 Referral centers must have a circulatory support
mobile unit available 24/7 and ready to intervene in
all healthcare centers in the region concerned (CR).
Organization of intensive care services
5.6 Each intensive care department must enter in a
national register all patients treated for severe
ARDS (CR).
5.7 Each intensive care department must be organized
through agreement to ensure the care of ARDS
patients requiring ECMO in each region.5.8I dentification in each region of at least one
intensive care department able to perform ECMO
within a referral center, or which has an
agreement with one of the referral centers (CR).
5.9 An intensive care department able to perform
ECMO in ARDS must: 1) acquire and maintain
specific skills, 2) have at least two trained
physicians in its medical personnel, 3) have access
to emergency vascular and thoracic surgery,
4) implement a regular training program for
paramedical staff, 5) formalize the indications and
ensure their traceability, 6) enter data in the severe
ARDS registry, and 7) at least once a year during
morbidity-mortality reviews analyze all the medical
records of patients treated with ECMO (CR).
5.10 Maintenance of the ECMO skills of an intensive
care department may be compromised if there are
fewer than ten indications for ECMO annually.
Specifics of pediatric care
5.11Pediatric care requires inter-regional organization
around pediatric referral centers (specialized
pediatric intensive care) with all human and
material means essential for the care of ARDS
patients and the setting up and use of
extracorporeal life support techniques: intensive
care, cardiac surgery and a circulatory support
mobile unit (CR).
5.12 To expedite ECMO in children, the pediatric
referral center (specialized pediatric intensive care)
should be contacted early (CR).
Perspectives
Concerning future developments, the jury of the Consen-
sus Conference offers the following comments:
 Current lack of knowledge concerning the
epidemiology of severe ARDS in France constitutes
a major obstacle to the implementation of a
reasoned strategy for use of extracorporeal life
support techniques, notably ECMO. The jury wants
to see the creation of a national registry of severe
ARDS as a response to this failing.
 Randomized, prospective, multicenter studies and
national registers should, in the years to come, yield
the indications for VV ECMO in the management of
severe ARDS.
 There is no recognized indication for ECCO2R,
which should only be used in ARDS in clinical
research by means of randomized, prospective,
multicenter studies and cohort studies. Pending the
results of these studies, heightened vigilance is
needed before any distribution of new equipment,
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benefit and cost-benefit ratios.
 The jury’s’ recommendations concerning the
proposed organization are designed to ensure
nationwide coverage of needs, which are limited at
present because there are few indications for VV
ECMO. These recommendations also proposed to
create a national network able to cope with
increased demand during an H1N1 influenza-like
epidemic and with any broadening of indications
stemming from ongoing trial results and the
anticipated increase in availability of equipment and
consumables.Additional file
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